Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
451 studies found for:    multiple myeloma | Open Studies | multiple myeloma
Show Display Options
Download search resultsDownload the search results for:
multiple myeloma | Open Studies | multiple myeloma (451 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine + Dexamethasone + Thalidomide
2 Recruiting Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138
Condition: Multiple Myeloma
Intervention: Biological: CART-138 cells
3 Recruiting High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: BeEAM
4 Recruiting A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
5 Recruiting Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine, Bortezomib, Prednisone
6 Recruiting Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: blood samples;   Biological: Bone marow samples
7 Recruiting Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Dexamethasone;   Drug: Bendamustine
8 Recruiting Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
9 Recruiting Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide;   Biological: pidilizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
10 Recruiting A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Melflufen;   Drug: Dexamethasone
11 Recruiting Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone
12 Recruiting TUMOR-ASSOCIATED ANTIGEN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR MULTIPLE MYELOMA
Condition: Multiple Myeloma
Intervention: Biological: TAA-specific CTLs
13 Not yet recruiting A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
Condition: Multiple Myeloma
Intervention: Drug: Denosumab Q4W
14 Recruiting Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Condition: Multiple Myeloma
Interventions: Drug: Melphalan;   Drug: Bortezomib
15 Not yet recruiting Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Condition: Smoldering Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Dexamethasone
16 Recruiting A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: AMG 224
17 Recruiting A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
Condition: Multiple Myeloma
Interventions: Drug: Revlimid;   Drug: Velcade;   Drug: dexamethasone;   Drug: Farydak
18 Recruiting A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Bortezomib
19 Not yet recruiting Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Metformin XR;   Drug: Dexamethasone
20 Recruiting A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.
Condition: Multiple Myeloma
Intervention: Drug: IMNOVID

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.